Article
Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Cancer science - 1 Apr 2016
Misumi Keizo, Sun Jiying, Kinomura Aiko, Miyata Yoshihiro, Okada Morihito, Tashiro Satoshi
Abstract excerpt
The epidermal growth factor receptor (EGFR) tyrosine kinase signaling pathways regulate cellular activities. The EGFR tyrosine kinase inhibitors (EGFR-TKIs) repress the EGFR pathway constitutively activated by somatic EGFR gene mutations and have drastically improved the prognosis of non-small-cell lung cancer (NSCLC) patients. However, some problems, including resistance, remain to be solved. Recently,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.